INTRODUCING THE FIRST* APPROVED ORAL AGENT FOR ADULTS WITH T1D AND BMI OF ≥27kg/m2 AS AN ADJUNCT TO INSULIN1

Individual is a model and not a real patient
*In the EU

In the EU, Forxiga 5 mg is indicated in adults for the treatment of insufficiently controlled Type 1 diabetes mellitus (T1D) as an adjunct to insulin in patients with a body mass index (BMI) ≥27kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. Treatment with Forxiga 5 mg is to be initiated and supervised by specialists in T1D.1

-

Forxiga 5 mg vs placebo demonstrated:

HbA1c reduction of ≥0.5%
without severe hypoglycaemia
in twice as many patients1

More time spent
within target
glucose range2

The additional benefit
of reductions in
body weight1**

HbA1c reduction of -0.5% without severe hypoglycaemia in twice as many patients1

More time spent within target glucose range2

The additional benefit of reductions in body weight1**

FORXIGA 5 mg HELPS YOUR PATIENTS
ACHIEVE GLYCAEMIC CONTROL1

Treatment with Forxiga 5 mg is to be initiated and supervised by specialists in T1D. Important safety information for healthcare professionals to minimise the risk of diabetic ketoacidosis can be found in the Risk Minimisation Materials. Available here:

RISK MINIMISATION MATERIALS

Country HCP materials Patient materials
Austria VIEW VIEW
Belgium Dutch VIEW VIEW
Belgium French VIEW VIEW
Belgium German Not applicable VIEW
Bulgaria VIEW VIEW
Croatia VIEW VIEW
Cyprus Forxiga is not currently available for T1D
Czech Republic VIEW VIEW
Denmark VIEW VIEW
Estonia VIEW VIEW
Finland Finnish VIEW VIEW
Finland Swedish VIEW VIEW
Germany VIEW VIEW
Greece Please contact AstraZeneca Medical Information & Patient Safety department in Greece for materials via phone by calling +30 210 6871 500
Hungary VIEW VIEW
Iceland VIEW VIEW
Ireland VIEW VIEW
Italy VIEW VIEW
Latvia VIEW VIEW
Lithuania VIEW VIEW
Luxemburg VIEW VIEW
Malta VIEW VIEW
Netherlands VIEW VIEW
Norway VIEW VIEW
Poland VIEW VIEW
Portugal Forxiga is not currently available for T1D
Romania VIEW VIEW
Slovakia Forxiga is not currently available for T1D (i.e. 5 mg dose)
Slovenia Forxiga is not currently available for T1D
Spain Forxiga is not currently available for T1D
Sweden VIEW VIEW

UNMET NEED
IN T1D

**Forxiga is not indicated for the management of weight loss. Weight change was a secondary endpoint in clinical trials.1

References

  1. FORXIGA. Summary of Product Characteristics. 2019. AstraZeneca.
  2. Rudofsky G. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes—the DEPICT-2 study. Presented at: 18th International Congress of Endocrinology; December 1-4, 2018; Cape Town, South Africa.
 

Loading......

Back to top